GENETIC POLYMORPHISM OF CYP2B6 AFFECTS THE PHARMACOKINETICS OF SIBUITRAMINE'S METABOLITE

被引：0
|
作者：
Cho, M. S. [1 ]
Jang, S. [1 ]
Lee, Y. [1 ]
Lim, L. [1 ]
Park, K. [1 ]
Chung, J. [1 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [41] EFFECTS OF CLOPIDOGREL AND CLARITHROMYCIN ON THE DISPOSITION OF SIBUTRAMINE AND ITS ACTIVE METABOLITE M1 AND M2 IN VIVO IN RELATION TO CYP2B6 GENETIC POLYMORPHISM.
    Pan, W.
    Bae, S. K.
    Shim, E. J.
    Park, S. E.
    Shon, J. H.
    Shin, J. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S8 - S8
  • [42] Effect of kidney disease on the hepatic CYP2B6 activity as measured by bupropion pharmacokinetics
    Miia, Turpeinen
    Niina, Koivuviita
    Ari, Tolonen
    Petri, Reponen
    Stefan, Lundgren
    Jouko, Miettunen
    Kaj, Metsarinne
    Anders, Rane
    Olavi, Pelkonen
    Kari, Laine
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 203 - 203
  • [43] Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations
    Xu, Bing-Ying
    Guo, Li-Ping
    Lee, Shui-Shan
    Dong, Qing-Ming
    Tan, Yi
    Yao, Hong
    Li, Li-Hua
    Lin, Che-Kit
    Kung, Hsiang-Fu
    He, Ming-Liang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (14) : 2100 - 2103
  • [44] EFFECTS OF CLOPIDOGREL AND CLARITHROMYCIN ON THE DISPOSITION OF SIBUTRAMINE AND ITS ACTIVE METABOLITE M1 AND M2 IN VIVO IN RELATION TO CYP2B6 GENETIC POLYMORPHISM.
    Pan, W.
    Bae, S. K.
    Shim, E. J.
    Park, S. E.
    Shon, J. H.
    Shin, J. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S1 - S1
  • [45] Bioactivation of chlorpyrifos by CYP2B6 variants
    Crane, Alice L.
    Klein, Kathrin
    Olson, James R.
    XENOBIOTICA, 2012, 42 (12) : 1255 - 1262
  • [46] Allele and genotype frequencies of CYP2B6 gene*5 polymorphism in a Turkish population
    Suzen, S.
    Artun, N. Y.
    TOXICOLOGY LETTERS, 2016, 258 : S78 - S79
  • [47] CYP2B6 18492T→C Polymorphism Compromises Efavirenz Concentration in Coinfected HIV and Tuberculosis Patients Carrying CYP2B6 Haplotype*1/*1
    Manosuthi, Weerawat
    Sukasem, Chonlaphat
    Thongyen, Supeda
    Nilkamhang, Samruay
    Manosuthi, Sukanya
    Sungkanuparph, Somnuek
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (04) : 2268 - 2273
  • [48] Synergism between CYP2B6 gene polymorphism and pxr-mediated induction
    Li, Haishan
    Wang, Hongbing
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32
  • [49] Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
    Zubiaur, Pablo
    Fernandez-Campos, Paula
    Navares-Gomez, Marcos
    Soria-Chacartegui, Paula
    Villapalos-Garcia, Gonzalo
    Roman, Manuel
    Mejia-Abril, Gina
    Ochoa, Dolores
    Abad-Santos, Francisco
    PHARMACEUTICS, 2021, 13 (10)
  • [50] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Milcah Dhoro
    Simbarashe Zvada
    Bernard Ngara
    Charles Nhachi
    Gerald Kadzirange
    Prosper Chonzi
    Collen Masimirembwa
    BMC Pharmacology and Toxicology, 16
12345